The presence of KRAS mutation in around 95% of pancreatic ductal adenocarcinoma (PDAC) cases has led to investigations on the relationship between p-p38 overexpression in PDAC cancer cells and patient survival [81]. The gene discussed is KRAS; the disease is pancreatic ductal adenocarcinoma.